discuss
articl
jaci
journal
club
blog
wwwjacionlineblogspotcom
respiratori
system
one
main
portal
entri
human
pathogen
although
precis
calcul
challeng
methodolog
inher
variabl
number
potenti
infecti
virus
breath
everi
day
rang
mani
thousand
thu
surpris
viral
respiratori
tract
infect
vrti
common
human
diseas
lead
enorm
health
econom
burden
wide
varieti
condit
fall
within
spectrum
vrti
mani
major
public
health
concern
influenza
acut
bronchiol
viral
pneumonia
common
cold
togeth
downstream
effect
ie
acut
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
result
vast
amount
morbid
mortal
health
care
cost
includ
primari
care
visit
hospit
death
also
inappropri
use
antibiot
loss
product
effect
qualiti
life
respiratori
tract
virus
isol
character
last
centuri
start
influenza
viru
ifv
follow
respiratori
syncyti
viru
rsv
coronavirus
adenovirus
rhinovirus
nevertheless
new
virus
subtyp
human
metapneumoviru
rhinoviru
c
still
identifi
even
though
sever
virus
typic
associ
clinicopatholog
entiti
eg
ifv
influenza
rsv
bronchiol
rhinoviru
common
cold
also
extens
overlap
often
difficult
identifi
etiolog
agent
base
clinic
ground
alon
consequ
consid
prevent
treatment
vrti
potenti
target
includ
specif
pathogen
immun
respons
diseas
transmiss
symptom
provid
overview
option
highlight
promis
approach
vrti
treatment
includ
symptomat
medic
immunomodulatori
drug
antivir
agent
natur
product
well
vrti
prevent
rang
vaccin
immunostimul
public
health
polici
vast
field
thu
emphas
advanc
might
relev
tackl
virusinduc
aspect
allerg
diseas
asthma
exacerb
mild
viral
respiratori
ill
manag
symptomat
overthecount
medic
nasal
decongest
antipyreticsanalges
antituss
expector
major
improv
foreseen
although
gener
well
toler
shortterm
relief
agent
advers
effect
especi
young
children
therefor
us
food
drug
administr
issu
warn
use
overthecount
cough
cold
product
children
younger
year
age
furthermor
use
decongest
minim
especi
children
wherea
codein
restrict
children
european
medic
agenc
sinc
select
cox
inhibitor
celecoxib
mesalazin
wide
use
clinic
antipyret
analges
antiinflammatori
properti
patient
airway
diseas
wherea
combin
neuraminidas
inhibitor
nai
significantli
improv
surviv
ifvinfect
mice
recent
studi
reveal
new
genu
special
proresolv
lipid
mediat
spm
includ
lipoxin
resolvin
protectin
maresin
enhanc
antiinflammatori
antivir
proresolv
mechan
medic
interf
prostanoid
lipoxygenas
biosynthesi
signal
thu
affect
resolut
spm
switch
aspirin
nonsteroid
antiinflammatori
drug
suggest
potenti
agent
modul
antivir
immun
wherea
sever
spm
resolut
agonist
clinic
develop
program
symptomat
relief
also
sought
sever
case
noninvas
ventil
reduc
respiratori
distress
patient
acut
viral
bronchiol
recent
new
devic
deliv
total
condit
ga
rel
humid
highflow
nasal
cannula
lmin
indic
bronchiol
mainli
rescu
therapi
reduc
need
admiss
intens
care
unit
immun
antivir
pathway
modul
although
vrti
often
shortliv
event
impair
antivir
clearanc
andor
activ
inflammatori
pathway
lead
import
downstream
complic
exacerb
asthma
copd
immun
antivir
mechan
lead
infect
exacerb
scrutin
medic
target
pathway
evalu
promis
candid
reduc
diseas
burden
impair
interferon
product
observ
patient
variou
obstruct
respiratori
diseas
potenti
contribut
enhanc
suscept
andor
sever
virusinduc
acut
airway
exacerb
although
inhal
ifnb
supplement
shown
clear
effect
prevent
virusinduc
symptom
worsen
patient
mild
asthma
subanalysi
patient
sever
asthma
show
protect
effect
interestingli
experiment
model
exogen
administr
induc
strong
prolong
antivir
state
ifnb
moreov
experiment
studi
allerg
asthma
model
show
ifnl
supplement
enhanc
h
immun
induc
ifng
suppress
h
h
respons
modul
lung
dendrit
cell
function
novel
antibodybas
drug
antirhinoviru
immunomodulatori
effect
act
ifnb
induct
suppress
h
respons
experiment
model
prototyp
synthet
tolllik
receptor
tlr
antagonist
eritoran
igg
therapi
shown
block
ifv
lethal
mice
suppress
lung
patholog
clinic
symptom
viral
titer
innat
immun
receptor
also
potenti
hosttarget
therapeut
approach
interestingli
omalizumab
antiig
mab
prevent
asthma
exacerb
either
decreas
durat
shed
rhinoviru
infect
block
synergist
effect
rhinoviru
infect
allergi
highaffin
ige
receptor
crosslink
plasmacytoid
dendrit
cell
reduc
ifna
respons
viral
infect
plausibl
omalizumab
enhanc
virusinduc
ifna
product
asthmat
patient
thu
limit
viru
spread
infect
sever
sever
cytokin
storm
entiti
associ
markedli
higher
level
proinflammatori
cytokin
associ
sever
influenza
infect
immunomodulatori
agent
propos
potenti
therapeut
strategi
peroxisom
proliferatoractiv
receptor
g
agonist
eg
rosiglitazon
pioglitazon
critic
regul
inflamm
promis
improv
clinic
outcom
sever
influenza
infect
develop
slow
possibl
cardiovascular
side
effect
howev
us
food
drug
administr
lift
restrict
base
new
safeti
data
moreov
receptor
agonist
locat
mainli
pulmonari
endotheli
cell
exhibit
cytokin
stormblunt
activ
suppress
innat
cellular
cytokinechemokin
respons
particularli
combin
antivir
agent
increas
interest
use
macrolid
treat
prevent
virusinduc
asthma
exacerb
although
microbi
resist
remain
major
hurdl
therefor
current
indic
earli
vivo
evid
suggest
azithromycin
antiinflammatori
antivir
effect
induct
interferonstimul
gene
mrna
express
reduc
viral
replic
releas
patient
asthma
chronic
obstruct
lung
diseas
random
clinic
trial
includ
wheez
preschoolag
children
earli
azithromycin
administr
significantli
reduc
likelihood
sever
lower
respiratori
tract
infect
novel
macrolid
mycobacterium
avium
complex
antiinflammatori
antibacteri
importantli
interferonaug
activ
airway
epithelium
identifi
final
vitro
model
demonstr
antitrypsin
exert
antiinflammatori
effect
airway
epitheli
cell
rhinovirusinfect
patient
copd
potenti
inhibit
activ
suggest
antitrypsin
potenti
antiinflammatori
agent
antivir
vrti
usual
character
acut
selflimit
cours
mean
peak
viral
replic
usual
preced
parallel
appear
clinic
symptom
result
time
window
verif
andor
type
pathogen
allow
specif
therapeut
intervent
extrem
narrow
addit
challeng
need
overcom
structur
variat
viral
protein
multipl
genotyp
high
mutat
rate
accordingli
limit
number
specif
antivir
drug
current
licens
promis
approach
mostli
aim
control
sever
complic
reduc
diseas
burden
transmiss
antivir
strategi
aim
block
particular
stage
viral
lytic
cycl
includ
attach
entri
host
cell
replic
transcript
translat
fig
principl
prevent
viral
pathogen
enter
host
cell
repres
ideal
antivir
strategi
viru
allow
hack
host
ifv
nai
success
use
competit
bind
sialic
acidbind
pocket
neuroaminidas
good
exampl
approach
oseltamivir
zanamivir
use
antiflu
therapi
wherea
laninamivir
peramivir
show
antivir
activ
wildtyp
also
oseltamivirresist
nairesist
strain
respect
nonenvelop
rhinovirus
use
viral
capsid
structur
bind
receptor
intercellular
adhes
molecul
lowdens
lipoprotein
receptor
cadherinrel
famili
member
even
though
rhinoviru
strain
use
cell
entri
competitor
tremacamra
make
clinic
despit
initi
promis
result
drug
current
avail
anoth
strategi
prevent
capsid
uncoat
assembl
new
virion
strategi
success
use
ifv
sever
acut
respiratori
syndrom
sar
coronaviru
use
class
fusion
mechan
fludas
nexbio
inc
san
diego
calif
fusion
construct
cleav
sialic
acid
receptor
host
cell
antivir
spectrum
includ
ifv
parainfluenza
virus
piv
nonenvelop
virus
rhinoviru
releas
genom
conform
shift
capsid
protein
accompani
expans
viral
shell
along
open
symmetryrel
channel
pore
genom
releas
viru
uncoat
variou
capsidbind
compound
rhinovirus
test
r
win
seri
without
ultim
success
pleconaril
vapendavir
pocapavir
still
clinic
evalu
note
major
drawback
capsid
binder
rapid
emerg
resist
sever
fusion
inhibitor
develop
treatment
rsv
review
elsewher
limit
code
capac
virus
reli
product
polyprotein
need
cleav
function
subunit
viral
proteas
enteroviru
polyprotein
cleav
famili
cystein
proteas
highli
conserv
among
differ
subtyp
lack
homolog
human
proteas
unfortun
fail
attempt
ruprintrivir
show
antivir
activ
vitro
vivo
similar
agent
pursu
current
use
hiv
proteas
inhibitor
lopinavir
ritonavir
patient
sar
associ
prove
benefit
although
retrospect
studi
report
sever
outcom
acut
respiratori
distress
syndrom
death
occur
less
often
receiv
combin
lopinavirritonavir
ribavirin
corticosteroid
polymeras
inhibitor
nucleosidenucleotid
analog
act
lead
termin
polynucleotid
chain
elong
ribavirin
use
treatment
sever
rsvrelat
diseas
highrisk
infant
combin
proteas
inhibitor
patient
sar
use
limit
cost
unconfirm
efficaci
toward
sever
outcom
promis
oral
bioavail
prodrug
novel
rsv
replic
inhibitor
cytidin
nucleosid
analogu
inhibit
rsv
replic
promis
polymeras
inhibitor
includ
amilorid
competit
inhibitor
coxsacki
viru
rna
polymeras
multipl
genera
picornavirida
still
earli
stage
favipiravir
antivir
drug
select
inhibit
rnadepend
rna
polymeras
ifv
well
sever
virus
umifenovir
shown
inhibit
variou
human
respiratori
rna
virus
includ
sever
strain
ifva
ifvb
rsv
rhinoviru
also
demonstr
inhibitori
activ
virus
envelop
respons
emerg
global
preval
infecti
diseas
final
promis
also
challeng
antivir
approach
use
antisens
oligonucleotid
antisens
oligonucleotid
singlestrand
deoxyribonucleotid
oligom
sequenc
complementari
target
mrna
transcript
thu
viral
genom
rna
viral
mrna
target
directli
antisens
technolog
rna
interfer
experiment
explor
target
measl
viru
sarscoronaviru
coxsackieviru
enterovirus
rhinovirus
piv
human
metapneumoviru
ifv
rsv
genom
rna
inhibitionbas
therapeut
furthest
advanc
clinic
develop
time
rsv
unmodifi
nake
small
interf
rna
design
inhibit
replic
rsv
interrupt
synthesi
viral
n
protein
sequenc
target
well
conserv
throughout
natur
occur
rsv
b
genotyp
new
antivir
explor
continu
particularli
lifethreaten
virus
ifv
influenza
rsv
rhinovirus
even
though
simpl
term
genom
organ
protein
code
prove
extrem
difficult
target
mostli
high
divers
immuneevad
strategi
also
extent
underestim
rhinoviru
infect
clinic
consequ
within
past
year
scientif
commun
world
shown
renew
interest
search
novel
immunestimul
antivir
agent
plant
origin
either
treatment
prevent
often
use
ethnopharmacolog
approach
natur
compound
wide
recogn
privileg
structur
trim
evolutionari
process
interact
macromolecular
target
plant
use
divers
set
biochem
pathway
gener
sever
secondari
metabolit
repres
ecosystem
adapt
help
plant
surviv
variou
environment
stress
protect
infect
infest
antivir
potenti
plant
extract
compound
vari
among
virus
natur
compound
occupi
equal
larg
complex
chemic
space
synthet
compound
case
antivir
agent
entiti
regist
last
approxim
year
classifi
natur
product
botan
synthet
natur
product
mimic
natur
product
pharmacophor
combin
latter
oseltamivir
success
stori
ifv
drug
synthesi
root
natur
abund
plant
constitu
quinic
acid
shikim
acid
use
start
materi
screen
strategi
appli
investig
crude
extract
plant
speci
inhibit
potenti
toward
nai
clostridium
perfringen
moreov
bioactiv
compound
cleistocalyx
operculatu
bud
discov
use
antiifv
screen
approach
chines
academi
medic
scienc
test
plant
among
pronounc
neuroaminidaseinhibit
effect
observ
herb
extract
elsholtzia
rugulo
extract
agrimonia
pilosa
echinacea
purpurea
prunu
mume
multicompon
mixtur
polyphenol
fraction
punica
granatum
secoiridoid
glucosid
ligustrum
lucidum
shown
signific
reduct
virusinduc
cytopath
effect
gener
antivir
antiinfluenza
activ
risk
reduct
common
cold
incid
use
echinacea
speci
supplement
shown
moreov
recent
metaanalysi
demonstr
benefit
longterm
month
prevent
echinacea
speci
recurr
respiratori
tract
infect
rti
anoth
promis
compound
bno
fix
combin
herbal
substanc
significantli
reduc
symptom
led
faster
recoveri
patient
acut
viral
rhinosinus
report
antivir
effect
natur
product
regardless
whether
obtain
clinic
trial
empir
knowledg
give
clue
research
howev
appear
enter
new
golden
age
natur
product
drug
discoveri
prevent
viral
respiratori
ill
attempt
either
avoid
exposur
strengthen
immun
defens
either
nonspecif
immunostimul
specif
vaccin
often
alway
intervent
target
toward
highrisk
group
particular
infect
eg
rsv
infant
elderli
ifv
patient
asthma
varieti
compound
microbi
herbal
synthet
origin
use
still
develop
nonspecif
immunostimulatori
agent
enhanc
modul
immun
respons
respiratori
pathogen
prevent
sometim
also
therapeut
context
effect
agent
usual
moder
therefor
use
secondari
support
measur
howev
potenti
underestim
among
sever
agent
base
bacteri
compon
bv
lw
pmbl
ru
bv
lyophilis
watersolubl
fraction
bacteria
commonli
detect
patient
rti
extens
studi
role
prevent
acut
recurr
rti
shown
mechanist
studi
confirm
pleiotrop
immunomodul
effect
innat
adapt
immun
pidotimod
synthet
dipeptid
molecul
induc
varieti
immunomodulatori
effect
shown
efficaci
prevent
rti
although
alway
confirm
probiot
supplement
shown
reduc
incid
durat
sever
upper
respiratori
tract
infect
immun
modul
particular
rhinoviru
infect
alter
nasal
innat
inflammatori
respons
vitamin
modulatori
role
host
defens
inflamm
immun
epitheli
repair
respiratori
tract
infect
recent
metaanalysi
confirm
vitamin
supplement
reduc
overal
risk
acut
respiratori
tract
infect
data
vitro
rhinovirusinfect
human
primari
bronchial
epitheli
cell
show
exogen
vitamin
reduc
rhinoviru
replic
increas
interferon
cathelicidin
gene
express
signific
amount
research
still
dedic
efficaci
vitamin
supplement
although
without
controversi
hope
specif
indic
consolid
soon
despit
widespread
use
multitud
studi
role
vitamin
c
zinc
supplement
still
inconclus
relat
action
common
cold
interestingli
medit
exercis
might
significantli
contribut
reduct
rti
burden
suggest
immunostimulatori
capac
nonpharmacolog
measur
also
consid
high
transmiss
rate
epidem
natur
respiratori
tract
virus
indic
effect
public
health
measur
reduc
transmiss
substanti
role
overal
prevent
infect
plethora
studi
metaanalys
delin
import
contribut
health
polici
reduc
transmiss
epidem
respiratori
tract
virus
eleg
random
control
trial
autom
webbas
intervent
maxim
handwash
intent
associ
fewer
episod
influenzalik
ill
shorter
durat
symptom
fewer
antibiot
prescript
intervent
group
although
similar
result
regard
handwash
confirm
cochran
metaanalysi
hand
hygien
intervent
educ
set
unequivoc
effect
low
adher
hand
hygien
recommend
correl
higher
incid
ifv
infect
among
health
care
worker
pandem
use
face
mask
shown
highli
effect
interrupt
respiratori
viral
spread
demonstr
cluster
random
trial
reduc
odd
ratio
influenza
infect
secondari
attack
observ
intervent
group
face
mask
regularli
worn
commun
especi
asia
much
less
western
societi
taken
togeth
seem
public
health
measur
might
provid
valuabl
alli
decreas
burden
respiratori
tract
infect
commun
vaccin
mab
passiv
immun
relev
intervent
vaccin
ifv
rhinoviru
rsv
initi
develop
long
ago
although
mix
success
mostli
rapid
viru
evolut
improv
understand
vaccin
immunolog
technolog
develop
place
us
closer
ever
develop
highli
effect
vaccin
major
respiratori
tract
virus
mab
therapi
viral
infect
ebv
rituximab
rsv
palivizumab
provid
passiv
immun
licens
wherea
similar
agent
target
influenza
virus
preclin
develop
neutral
antibodi
bind
inactiv
virus
inhibit
viral
cell
entri
block
receptor
bind
conform
chang
prevent
releas
virion
cell
modul
immun
effector
function
engin
product
strategi
produc
antibodi
fragment
higheraffin
bind
longer
halflif
contribut
lower
overal
cost
therapi
although
vaccin
still
consid
prefer
case
notabl
effect
neutral
mab
epitop
also
inform
ration
design
vaccin
differ
type
vaccin
respiratori
virus
exist
shown
fig
tradit
either
live
attenu
inactiv
virus
use
recent
subunit
vaccin
made
detergentdisrupt
whole
virus
purifi
viral
protein
also
common
furthermor
promis
approach
use
microparticlenanoparticl
materi
recombin
technolog
produc
broadli
immunogen
often
selfadjuv
reproduc
safe
vaccin
respons
deliveri
system
includ
synthet
polym
virosom
viruslik
particl
vlp
liposom
lipid
nanoparticl
protein
emuls
immunestimul
complex
current
natur
occur
particl
favor
safeti
concern
even
though
synthet
polym
poli
lacticcoglycol
acid
use
gold
nanoparticl
shown
promis
result
selfassembl
protein
nanoparticl
ferritin
cage
vault
also
shown
promis
preclin
data
layerbylay
peptidefabr
vaccin
contain
altern
charg
polylglutam
acid
polyllysin
layer
rsv
peptid
ad
efficaci
anim
virosom
adjuv
vaccin
compos
reconstitut
ifv
envelop
effect
remov
core
protein
rna
avail
year
excel
toler
efficaci
sever
vlp
vaccin
base
hepat
b
viru
surfac
antigen
approv
viral
infect
human
papilloma
viru
microb
eg
malaria
although
ifv
candid
progress
nevertheless
vlp
offer
promis
valenc
similar
immun
present
pathogen
antigen
preserv
adjuv
form
vital
part
mani
vaccin
howev
aluminum
hydroxid
oil
water
emuls
current
approv
number
novel
adjuv
microcrystallin
tyrosin
matrix
pathogenassoci
molecular
pattern
chitosan
develop
dna
rna
vaccin
induc
immun
respons
nucleic
acidencod
antigen
impress
result
report
anim
singl
lowdos
intraderm
nonrepl
dna
vaccin
rsv
howev
whether
translat
effect
human
subject
yet
known
enhanc
immunogen
rna
vaccin
encapsul
nanoparticl
achiev
steril
immun
zika
viru
mice
well
incorpor
virusbas
selfrepl
construct
known
replicon
activ
ifv
vaccin
alreadi
form
core
global
strategi
sever
season
pandem
influenza
trival
recent
quadrival
vaccin
larg
efficaci
healthi
adult
provid
adequ
match
circul
vaccin
strain
higherdos
mg
vaccin
avail
elderli
patient
similarli
pandem
vaccin
offer
greater
crossclad
protect
presenc
improv
adjuv
current
frontier
ifv
vaccin
develop
univers
vaccin
tabl
ideal
would
protect
circul
pandem
strain
also
novel
epitop
might
evolv
futur
mani
vaccin
current
preclin
earli
clinic
stage
heterosubtyp
crossreact
antibodi
ifva
hemagglutinin
ha
stalk
isol
immun
subject
lead
mab
phase
similar
multilineag
hastalk
antibodi
ifvb
also
report
conserv
protein
also
target
antibodi
develop
therefor
passiv
immun
postinfect
treatment
might
soon
becom
anoth
tool
combat
ifv
hastalk
chimer
headstalkbas
vaccin
also
shown
encourag
preclin
result
vaccin
strategi
base
conserv
epitop
protein
np
involv
induct
tcell
immun
lead
develop
promis
mva
viral
vector
vaccin
vaccin
use
multiepitop
peptid
induc
ifvspecif
tcell
respons
reduc
viral
shed
human
subject
selfrepl
rna
nanoparticl
also
encod
multipl
protein
hepat
b
virusbas
vlp
express
ha
epitop
also
appear
promis
current
licens
vaccin
mab
palivizumab
approv
prevent
rsv
infect
howev
numer
candid
clinic
trial
recent
review
suptavumab
antif
mab
reach
phase
iii
trial
preterm
infant
offer
greater
potenc
palivizumab
extend
halflif
primat
suggest
per
season
dose
candid
vaccin
base
live
attenu
strain
subunit
vector
nanoparticl
technolog
rang
adjuv
chimer
combin
vaccin
use
express
vector
vlp
show
much
promis
recent
preclin
result
exhibit
effect
neutral
rsv
advanc
novavax
fprotein
vlp
nanoparticl
vaccin
aluminum
hydroxid
adjuv
phase
iii
matern
vaccin
transplacent
transmiss
neutral
antibodi
demonstr
preclin
studi
although
confer
signific
protect
rsv
recombin
dna
vaccin
also
promis
appar
abil
induc
balanc
h
h
respons
broad
iggiga
profil
mimick
live
rsv
challeng
intranas
oral
vaccin
formul
earli
stage
clinic
studi
fig
vaccin
type
live
attenu
vaccin
grown
cultur
make
less
virul
problem
revers
b
inactiv
vaccin
treat
uv
formaldehyd
crosslink
protein
make
nonviabl
c
protein
purifi
extract
dissolv
use
deterg
nake
nucleic
acid
also
use
vaccin
e
nanoparticl
vaccin
encompass
natur
synthet
materi
membran
use
make
liposom
contain
deliv
antigen
target
cell
f
virus
nucleic
acid
core
protein
remov
form
virosom
g
viral
protein
ha
stalk
antigen
engin
onto
immunogen
core
protein
eg
ferritin
vault
exampl
ha
ferritin
adapt
pbd
code
h
virus
vaccinia
viru
ankara
coat
protein
genet
materi
remov
engin
express
antigen
influenza
ion
channel
protein
vlp
engin
express
antigen
natur
glycosyl
protein
adjuv
incorpor
coat
pamp
pathogenassoci
molecular
pattern
j
synthet
nanoparticl
made
polym
polystyren
poli
lacticcoglycol
acid
gold
carbon
nanotub
peptid
adsorb
admix
encapsul
ag
antigen
initi
vaccin
attempt
recent
preclin
experi
show
inactiv
rhinoviru
vaccin
type
specif
crossneutr
howev
although
anim
rhinoviru
antibodi
respons
might
weakli
crossneutr
data
human
subject
suggest
respons
mainli
misdirect
intern
epitop
understand
full
extent
rhinoviru
divers
would
probabl
requir
develop
panspeci
vaccin
multipl
strategi
develop
reduc
burden
viral
respiratori
ill
like
mani
strategi
find
relev
indic
antivir
strategi
probabl
make
sens
sever
lifethreaten
situat
window
opportun
clearli
present
specif
viru
season
suscept
popul
ideal
prevent
wide
scale
immun
abl
reduc
overal
burden
respiratori
infect
huge
effect
appear
within
reach
rsv
ifv
wherea
addit
effort
need
toward
rhinoviru
meantim
symptomat
immunostimulatori
measur
provid
relief
hold
promis
relat
postvir
reactiv
airway
diseas
public
health
measur
expand
critic
reduc
effect
contain
potenti
epidem
